Johnson & Johnson said on Monday it would buy neurological drugmaker Intra-Cellular Therapies for $14.6 billion, its biggest ...

A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology ®, the medical journal of the ...

utilization by patients remains low due to high costs and similar effectiveness to existing drugs, a new study funded by the American Academy of Neurology finds. A research team led by Michigan ...

The sleep aid Ambien could be allowing toxic proteins to pollute the brain, potentially increasing a person’s risk of ...

the effects of newer antiseizure medications on their children was unknown," said Adam Hartman, M.D., program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS).

Leveraging Acadia’s extensive expertise in developing and commercializing advanced therapies for neurological disorders ... comprises two marketed drugs — Nuplazid (pimavanserin) and the ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

The records were reviewed of 43 patients with medication-overuse headache followed in a pediatric neurology clinic by a single provider (E.H.K.) over a 24-month period from October 2002 to ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.

A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology. The study looked at the drug ...